Corrections Log: What We Got Wrong, and When We Fixed It
Published: 2026-08-03 · Last reviewed: 2026-08-04 · Methodology v4.1
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · journal · corrections.
A publication that never corrects itself is not more accurate than one that does — it is less observable. Every correction is listed here in full, with what we said, what is correct and why it mattered.
Corrections are published at the same prominence as the original claim, and the affected pages carry the correction inline rather than being edited silently.
· COR-001 · Material — starter price quoted as the price of treatment
Every page quoting the approved oral semaglutide price
What we said: We described the approved oral semaglutide tablet as $149 a month without stating which doses that covers.
What is correct: The manufacturer's own price guide, read 4 August 2026, sets $149 for the 1.5 mg and 4 mg doses and $299 for the 9 mg and 25 mg maintenance doses. The $149 rate on 4 mg ends 31 August 2026, after which it becomes $199.
Why it mattered: Quoting a starter-dose figure as the price of treatment is the exact error we document in provider marketing. Every affected page now carries the full ladder.
· COR-002 · Material — availability
Peptide pages referencing BPC-157
What we said: BPC-157 was described alongside peptides available through compounding pharmacies without stating its regulatory status.
What is correct: BPC-157 is on the FDA's 503A Category 2 bulk drug substances list, which identifies substances raising significant safety risks that may not be used in compounding. It has no human efficacy trials.
Why it mattered: A reader comparing peptides needs to know which ones a legitimate pharmacy cannot legally compound. Omitting it made the list look like a menu.
What we said: Trial figures appeared on pages about compounded preparations without a consistent statement that the trials studied the approved product.
What is correct: Every efficacy figure on this site was collected on an FDA-approved product. No compounded preparation has a trial of its own, and no figure transfers to one.
Why it mattered: A number placed beside a product implies it describes that product.
How to report an error
Email the research desk with the page and the figure you believe is wrong. We would rather a figure be found and corrected than repeated. Response commitment and escalation route: the methodology.